Similar to our results, Tajima et al. [10] showed the frequencies of CD44- positive cases were increased after gemcitabine-based neoadjuvant chemotherapy and concluded CD44- positive cells were chemoresistant in pancreatic cancer. This evidence concerns the gene CD44 and pancreatic neoplasm.